title: [A case of therapy for bevacizumab-induced hypertension].
abstract: The patient was a 73-year-old female with sigmoid colon cancer, who underwent resection of sigmoid colon cancer and liver metastasis. She was treated with 5-fluorouracil and levofolinate calcium(sLV5FU2)plus bevacizumab(BV) for advanced colorectal cancer. She was treated with angiotensin II receptor blocker(ARB)because hersystolic blood pressure was 200 mmHg and her diastolic blood pressure 100 mmHg after five courses of BV therapy. As a result, her blood pressure was controlled. It was possible to administer BV. Therefore, ARB may be the preferred antihypertensive agent in the management of BV-induced hypertension.
authors.affiliation: Dept. of Pharmacy, Shonan Kamakura General Hospital, Japan.
authors.forename: Takeo
authors.initials: T
authors.lastname: Yasu
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Miyasaka
authors.forename: Hideo
authors.initials: H
authors.lastname: Chubachi
authors.forename: Rai
authors.initials: R
authors.lastname: Shimoyama
mesh_terms: D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000068258:Bevacizumab; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000556:secondary; D011945:Receptors, Angiotensin / Q000378:metabolism; D012811:Sigmoid Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000601:surgery
chemical_list: D057911:Angiotensin Receptor Antagonists; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D011945:Receptors, Angiotensin; D000068258:Bevacizumab